MX2017014782A - Metodo para el tratamiento de enfermedad neurologica. - Google Patents
Metodo para el tratamiento de enfermedad neurologica.Info
- Publication number
- MX2017014782A MX2017014782A MX2017014782A MX2017014782A MX2017014782A MX 2017014782 A MX2017014782 A MX 2017014782A MX 2017014782 A MX2017014782 A MX 2017014782A MX 2017014782 A MX2017014782 A MX 2017014782A MX 2017014782 A MX2017014782 A MX 2017014782A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- neurological disease
- neurologic diseases
- prophylaxis
- csf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención comprende un inhibidor de la actividad del CSF-1R para usarse en el tratamiento y/o profilaxis de enfermedades neurológicas y un nuevo método de tratamiento de enfermedades neurológicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15169367 | 2015-05-27 | ||
PCT/EP2016/061824 WO2016189045A1 (en) | 2015-05-27 | 2016-05-25 | Method for the treatment of neurological disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014782A true MX2017014782A (es) | 2018-02-15 |
Family
ID=53284033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014782A MX2017014782A (es) | 2015-05-27 | 2016-05-25 | Metodo para el tratamiento de enfermedad neurologica. |
Country Status (16)
Country | Link |
---|---|
US (1) | US10316097B2 (es) |
EP (1) | EP3303390A1 (es) |
JP (2) | JP6851322B2 (es) |
KR (1) | KR20180012279A (es) |
CN (2) | CN107660152B (es) |
AR (1) | AR104755A1 (es) |
AU (1) | AU2016269065B2 (es) |
BR (1) | BR112017025263A2 (es) |
CA (1) | CA2987146A1 (es) |
CO (1) | CO2017011778A2 (es) |
EA (1) | EA039951B1 (es) |
IL (1) | IL255506A (es) |
MA (1) | MA47395A (es) |
MX (1) | MX2017014782A (es) |
MY (1) | MY195000A (es) |
WO (1) | WO2016189045A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3600311B1 (en) * | 2017-03-28 | 2024-05-15 | Novartis AG | New methods for the treatment of multiple sclerosis |
WO2018222957A1 (en) * | 2017-06-01 | 2018-12-06 | Ovid Therapeutics Inc. | Treatment of developmental disorders with imidazolone derivatives |
US20220064310A1 (en) * | 2018-12-13 | 2022-03-03 | Development Center For Biotechnology | Anti-human csf-1r antibody and uses thereof |
US11419317B2 (en) | 2019-01-28 | 2022-08-23 | Central Institute For Experimental Animals | Non-human animal having human IL-34 and use Thereof |
JP2023508189A (ja) * | 2019-12-24 | 2023-03-01 | アダジーン(スージョウ)リミテッド | 抗csf1r分子及びその使用 |
CN112924698A (zh) * | 2021-03-05 | 2021-06-08 | 厦门大学 | 一种用于诊断神经退行性疾病的生物标志物及其应用 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | 新規な結合タンパク質の生成と選択 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
AU1736495A (en) | 1994-01-31 | 1995-08-15 | Trustees Of Boston University | Polyclonal antibody libraries |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
WO2001030381A2 (de) * | 1999-10-28 | 2001-05-03 | Hofbauer, Reinhold | Verwendung von csf-1-inhibitoren |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
WO2004044159A2 (en) * | 2002-11-12 | 2004-05-27 | Incyte Corporation | Receptors and membrane-associated proteins |
JP4603894B2 (ja) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | 抗体産生細胞を同定するためのアッセイ |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
PL1644412T5 (pl) | 2003-07-01 | 2019-01-31 | Ucb Biopharma Sprl | Modyfikowane fragmenty Fab przeciwciała |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
KR20090090487A (ko) * | 2008-02-21 | 2009-08-26 | 재단법인서울대학교산학협력재단 | 글루코코르티코이드계 화합물을 포함하는 뇌신경질환의 치료 또는 예방용 약학 조성물 |
BRPI0909044B8 (pt) * | 2008-03-14 | 2021-05-25 | Transgene Sa | anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos |
US8470977B2 (en) * | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
US8080246B2 (en) * | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
WO2010127143A2 (en) * | 2009-04-29 | 2010-11-04 | Purapharm International (Hk) Limited | Neuroprotective ganoderma compositions and methods of use |
EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
CN102918060B (zh) | 2010-03-05 | 2016-04-06 | 霍夫曼-拉罗奇有限公司 | 抗人csf-1r抗体及其用途 |
AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
LT2566517T (lt) * | 2010-05-04 | 2019-01-10 | Five Prime Therapeutics, Inc. | Antikūnai, surišantys csf1r |
US9161968B2 (en) * | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
HUE032754T2 (en) * | 2011-05-05 | 2017-10-30 | Novartis Ag | CSF-1R inhibitors for the treatment of brain tumors |
WO2013119716A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
US9358235B2 (en) * | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US20150119267A1 (en) * | 2012-04-16 | 2015-04-30 | Sloan-Kettering Institute For Cancer Research | Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer |
CN103127164A (zh) * | 2013-01-06 | 2013-06-05 | 威海康博尔生物药业有限公司 | 一种调节小胶质细胞激活状态的κ-卡拉胶寡糖的应用 |
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
AU2015339306B2 (en) * | 2014-10-29 | 2021-07-22 | Bristol-Myers Squibb Company | Combination therapy for cancer |
WO2016097420A1 (en) * | 2014-12-19 | 2016-06-23 | Universite De Nantes | Anti il-34 antibodies |
WO2016196679A1 (en) * | 2015-06-02 | 2016-12-08 | Genentech, Inc. | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
-
2016
- 2016-05-25 US US15/577,035 patent/US10316097B2/en not_active Expired - Fee Related
- 2016-05-25 EA EA201792610A patent/EA039951B1/ru unknown
- 2016-05-25 MX MX2017014782A patent/MX2017014782A/es unknown
- 2016-05-25 CA CA2987146A patent/CA2987146A1/en not_active Abandoned
- 2016-05-25 AU AU2016269065A patent/AU2016269065B2/en not_active Expired - Fee Related
- 2016-05-25 CN CN201680030517.2A patent/CN107660152B/zh not_active Expired - Fee Related
- 2016-05-25 CN CN202111207345.0A patent/CN113940996A/zh active Pending
- 2016-05-25 JP JP2017561376A patent/JP6851322B2/ja active Active
- 2016-05-25 KR KR1020177036084A patent/KR20180012279A/ko unknown
- 2016-05-25 WO PCT/EP2016/061824 patent/WO2016189045A1/en active Application Filing
- 2016-05-25 MA MA047395A patent/MA47395A/fr unknown
- 2016-05-25 MY MYPI2017704420A patent/MY195000A/en unknown
- 2016-05-25 BR BR112017025263A patent/BR112017025263A2/pt active Search and Examination
- 2016-05-25 EP EP16727353.1A patent/EP3303390A1/en not_active Withdrawn
- 2016-05-27 AR ARP160101526A patent/AR104755A1/es unknown
-
2017
- 2017-11-07 IL IL255506A patent/IL255506A/en unknown
- 2017-11-20 CO CONC2017/0011778A patent/CO2017011778A2/es unknown
-
2020
- 2020-11-24 JP JP2020194268A patent/JP2021059541A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CO2017011778A2 (es) | 2018-04-19 |
IL255506A (en) | 2018-04-30 |
WO2016189045A1 (en) | 2016-12-01 |
JP2018522826A (ja) | 2018-08-16 |
EA201792610A1 (ru) | 2018-06-29 |
JP6851322B2 (ja) | 2021-03-31 |
MY195000A (en) | 2022-12-30 |
EA039951B1 (ru) | 2022-03-31 |
EP3303390A1 (en) | 2018-04-11 |
JP2021059541A (ja) | 2021-04-15 |
AR104755A1 (es) | 2017-08-09 |
BR112017025263A2 (pt) | 2018-08-07 |
CN107660152A (zh) | 2018-02-02 |
CN107660152B (zh) | 2021-11-05 |
AU2016269065A1 (en) | 2017-12-07 |
MA47395A (fr) | 2019-12-11 |
US20180142026A1 (en) | 2018-05-24 |
CN113940996A (zh) | 2022-01-18 |
AU2016269065B2 (en) | 2022-06-02 |
KR20180012279A (ko) | 2018-02-05 |
CA2987146A1 (en) | 2016-12-01 |
US10316097B2 (en) | 2019-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288712A (en) | Methods for treating abnormal movement disorders | |
IL298690B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
PH12017500601A1 (en) | Anti-tnf compounds | |
PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
MX2017014782A (es) | Metodo para el tratamiento de enfermedad neurologica. | |
MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
PH12017501990B1 (en) | Imidazopyrazinones as pde1 inhibitors | |
EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
ZA201906213B (en) | Compounds and methods for the treatment of parasitic diseases | |
IL269698B (en) | Methods for preventing or treating eye diseases | |
PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
NZ723269A (en) | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | |
MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci |